IREB2 and breast carcinoma: Initially, we assessed the cytotoxic effects of the IRP2 inhibitor, KS-20226, and found that it markedly diminished the viability of all four breast cancer cell lines (Fig. 3A), with IC50 values demonstrating a negative correlation with basal IRP2 protein expression (Fig. S2A).